This open-label, single arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs. Patients will receive tocilizumab (8mg/kg iv infusion) every 4 weeks in addition to their current DMARD therapy. Anticipated time on study treatment is 48 weeks, and the target sample size is <100.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00996606?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
